Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Novo Nordisk

Elon Musk and Bernie Sanders say they agree on one thing—cheaper Ozempic

Novo Nordisk is investing $30 billion to expand production, but middlemen are pocketing 74 cents of every dollar it makes in sales.

Fortune

Novo Nordisk CEO blames PBMs, insurers for Ozempic price tag - Roll Call

Senate HELP Chairman Bernie Sanders launches another salvo in drug pricing war, this one aimed at popular weight loss drugs.

Roll Call

Novo Nordisk CEO takes aim at U.S. health system in Ozempic testimony

Novo Nordisk's CEO said the complexities of the U.S. healtchare system prevented access to $1,349 Wegovy.

Fortune

From analysis to the latest developments in health,
read the most diverse news in one place.

Analysts say market forces will lower cost of obesity drugs - Roll Call

Hearing on weight loss drug prices will feature CEO of Novo Nordisk and comes after threats to subpoena company executives.

Roll Call

Snag This Biotech Stock Before November, Here's Why

With Viking Therapeutics making a splash in the weight-loss drug arena, one analyst is encouraging investors to snap up the stock before a November catalyst.

Barchart

Ozempic, Wegovy, Rybelsus: Are we losing sight of overall health? Here’s what the science says

The craze for new drugs in the GLP-1 (Glucagon-like peptide 1) and GIP (Gastric inhibitory polypeptide) analogue class, better known under the trade names Ozempic and Wegovy, is remarkable, but it’s not totally unprecedented in the history of pharmaceutical blockbusters.

The Conversation

With Obesity Drug Demand Surging, Is Novo Nordisk a Buy?

Novo Nordisk (NVO) continues strengthening its obesity portfolio and marking new milestones. The company’s solid product demand, strategic investments, and developments are the key drivers for its growth and success. So, let’s examine whether NVO is an ideal investment choice. Read more to find out.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

Weight-loss drug Saxenda effective for kids as young as 6, study shows

A drug approved to treat obesity in adults and teens is safe and effective for use in kids as young as 6, when combined with diet and exercise

The Independent UK

Ozempic maker sued over claims the weight-loss medication led to woman’s colon removal

Doctors had to remove parts of her intestines due to what she claims were side effects from taking weight-loss medication

The Independent UK

Scientists Confirmed An Important Connection Between Semaglutide and Mental Health

Researchers found that semaglutide, compared with a placebo, didn't significantly increase depressive thoughts.

Inverse

Denmark gets Novo Nordisk to lower Ozempic prices

As Congress pushes for Medicare to cover anti-obesity drugs, puzzlement remains about who should get them, for how long, and at what price.

Fortune

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

The Guardian - UK

Weight loss drug Ozempic sales grow nearly 50% in the US, says maker Novo Nordisk

A surge in demand for weight loss drug Ozempic has helped Novo Nordisk post a 25% jump in revenues in the first half of the year, the Danish company said today.

Evening Standard

Should You Be Investing in Nordic Companies?

Should you be Investing in Nordic companies? This corner of Europe presents unique opportunities for investors.

Kiplinger

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - UK

Weight-loss drug could help slow Alzheimer’s cognitive decline, trial finds

Liraglutide appeared to reduce brain shrinkage in people with early-stage Alzheimer’s, a small UK study reports

Al Jazeera

Surging demand, soaring price tags lead to fake Ozempic doses

A rise in counterfeit versions of sought-after weight loss drug has led to a series of hospitalisations.

Fortune

Swiss pharma giant Roche is ‘fast-tracking’ development of an experimental Wegovy challenger pill for weight loss

Roche is working on bringing its weight-loss medications to patients "faster than anticipated,” making it yet another contender in the weight-loss drug market.

The Independent UK

Weight-loss jab to be used to prevent other health problems

Some 17,600 people took part in the trial and were either prescribed Wegovy or a dummy drug

Get all your
news in one place.

100's of premium titles.
One news app.

The Guardian - US

Ozempic knockoffs flood US market thanks to ‘blind spot’ in FDA rules

Pharmacy alliance president counters that ‘it’s an intentional policy’ so patients don’t go without medication

The Independent UK

Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

Zenger

Big Pharma’s Monopoly On Ozempic Threatens Access To Diabetes Drug In Communities Of Color

Small pharmacies find difficulty in prescribing the drug due to Big Pharma restrictions on the industry. ‌

StockNews.com

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

Fortune

These weight-loss startups tell customers they can stop taking Ozempic or Wegovy and stay thin. Doctors disagree

As nearly $1 billion of venture capital dollars have been injected into weight-loss startups since 2023, companies are making unproven claims to attract customers. It’s a new twist on a story as old as the diet industry.

The Independent UK

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

International Business Times

Eli Lilly Weight Loss Drug Beats Ozempic In Head-to-head Study

Patients taking Eli Lilly's new drug Mounjaro achieved significantly greater weight loss than those on Novo Nordisk's Ozempic, a head-to-head study published Monday showed.

1 … 17 18 19 20

People

Lars Fruergaard Jørgensen

18 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Imperial College London

318 stories

Viking

315 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.